Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
Net Income (Common)
Gilead Sciences Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Moderna Inc
NASDAQ:MRNA
|
Net Income (Common)
-$4.7B
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Gilead Sciences Inc's Net Income (Common)?
Net Income (Common)
5.7B
USD
Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Net Income (Common) amounts to 5.7B USD.
What is Gilead Sciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
6%
Over the last year, the Net Income (Common) growth was 23%. The average annual Net Income (Common) growth rates for Gilead Sciences Inc have been 258% over the past three years , 1% over the past five years , and 6% over the past ten years .